Table 2.
Critical trials of stem cell therapy in peripheral arterial disease (≥10 patients)
| Authors | Disease | Stem cell source | Route of cell application | Results |
|---|---|---|---|---|
| Tateishi-Yuyama E, et al. 2002 | ASO* | Bone marrow-derived mononuclear cells and peripheral blood mononuclear cells (as a control) | Intramuscular | Improvement: Pain free walking time, rest pain, ABI‡, TcPO2§ |
| Miyamoto K, et al. (37) 2004 | ASO*+TAO† | Bone marrow-derived mononuclear cells | Intramuscular | Improvement: Pain free walking time, VAS‖, and ABI‡ |
| Kawamura A, et al. (38) 2005 | ASO* | Peripheral blood stem cells (CD34 positive cells) | Intramuscular | Prevention of limb amputation: 22 limbs of 30 limbs (73%) |
| Huang P, et al. 2005 (39) | ASO* | Peripheral blood mononuclear cells | Intramuscular | Improvement: Pain, wound healing, ABI‡ |
| Kawamura A, et al. (40) 2006 | ASO* | Peripheral blood stem cells (CD34 positive cells) | Intramuscular | Improvement: subjective symptoms, temperature Visualization of arteries on CT |
| Bartsch T, et al. (41) 2006 | ASO* | Bone marrow-derived mononuclear cells | Combined intramuscular and intraarterial | Improvement: walking distance, ABI‡, perfusion |
| Kim DI, et al. (42) 2006 | TAO† | Whole bone marrow | Fenestration through tibia bone | Improvement: Ischemic symptoms and wound healing Development of collateral vessels on angiography |
| Durdu S, et al. (43) 2006 | TAO | Bone marrow-derived mononuclear cells | Intramuscular | Improvement: Rest pain, peak walking time, QOL¶, ABI‡ Development of collateral vessels (angiography) |
ASO*: Atherosclerosis obliterans,
TAO†: Thromboangiitis obliterans,
ABI‡: Ankle-brachial index,
TcPO2§: Transcutaneous oxygen pressure,
VAS‖: Visual analog scale,
QOL¶: Quality of life.